A Double Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Investigate the Safety, Tolerability, Food Effect, and Pharmacokinetics of JNJ-54416076 in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 30 Sep 2016
At a glance
- Drugs JNJ 54416076 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Janssen Research & Development
- 23 Sep 2016 Status changed from active, no longer recruiting to completed.
- 14 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 03 Aug 2016 Planned End Date changed from 1 Aug 2016 to 1 Sep 2016.